Prospect of targeting the CD40 pathway for cancer therapy

Clinical Cancer Research

Volumn 13, Issue 4, 2007, Pages 1083-1088

  Vonderheide, Robert H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CP 870 893; HCD 122; RECOMBINANT CD40 LIGAND; SGN 40; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

CANCER PATIENT; CANCER STAGING; CANCER THERAPY; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR REGRESSION;

ANTIGENS, CD40; HUMANS; NEOPLASMS;

EID: 33947223664     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1893     Document Type: Review

References (78)

1. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16: 111-35.
2. van Kooten C, Banchereau J. CD40-40 ligand. J Leukoc Biol 2000;67:2-17.
3. Young LS, Eliopoulos AG, Gallagher NJ, Dawson CW. CD40 and epithelial cells: across the great divide. Immunol Today 1998;19:502-6.
4. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004;22:307-28.
5. Armitage RJ, Fanslow WC, Strockbine L, et al. Molecular and biological characterization of a murine ligand for CD40. Nature 1992;357:80-2.
6. Dadgostar H, Zarnegar B, Hoffmann A, et al. Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes. Proc Natl Acad Sci U S A 2002;99:1497-502.
7. Allen RC, Armitage RJ, Conley ME, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 1993;259:990-3.
8. Ferrari S, Giliani S, Insalaco A, et al. Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc Natl Acad Sci U S A 2001;98:12614-9.
9. Etzioni A, Ochs HD. The hyper IgM syndrome - an evolving story. Pediatr Res 2004;56:519-25.
10. Castigli E, Alt FW, Davidson L, et al. CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation. Proc Natl Acad Sci U S A 1994;91:12135-9.
11. Kawabe T, Naka T, Yoshida K, et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1994;1:167-78.
12. Renshaw BR, Fanslow WC III, Armitage RJ, et al. Humoral immune responses in CD40 ligand-deficient mice. J Exp Med 1994;180:1889-900.
13. Xu J, Foy TM, Laman JD, et al. Mice deficient for the CD40 ligand. Immunity 1994;1:423-31.
14. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998;393:478-80.
15. + T-helper and a T-killer cell. Nature 1998;393: 474-8.
16. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-40L interactions. Nature 1998; 393:480-3.
17. French RR, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999;5:548-53.
18. Diehl L, den Boer AT, Schoenberger SP, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 1999;5:774-9.
19. + T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999;5:780-7.
20. Dallman C, Johnson PW, Packham G. Differential regulation of cell survival by CD40. Apoptosis 2003; 8:45-53.
21. Choi MS, Boise LH, Gottschalk AR, Quintans J, Thompson CB, Klaus GG. The role of bcl-XL in CD40-mediated rescue from anti-μ-induced apoptosis in WEHI-231 B lymphoma cells. Eur J Immunol 1995;25:1352-7.
22. Sarma V, Lin Z, Clark L, et al. Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis. J Biol Chem 1995;270:12343-6.
23. Zhang X, Li L, Choe J, et al. Up-regulation of Bcl-xL expression protects CD40-activated human B cells from Fas-mediated apoptosis. Cell Immunol 1996; 173:149-54.
24. Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G. NF-κB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci U S A 1999;96:9136-41.
25. Granziero L, Ghia P, Circosta P, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001;97:2777-83.
26. Wingett DG, Vestal RE, Forcier K, Hadjokas N, Nielson CP. CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res Treat 1998;50:27-36.
27. Afford SC, Randhawa S, Eliopoulos AG, Hubscher SG, Young LS, Adams DH. CD40 activation induces apoptosis in cultured human hepatocytes via induction of cell surface fas ligand expression and amplifies fas-mediated hepatocyte death during allograft rejection. J Exp Med 1999;189:441-6.
28. Grell M, Zimmermann G, Gottfried E, et al. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J 1999;18:3034-43.
29. Eliopoulos AG, Davies C, Knox PG, et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol 2000;20:5503-15.
30. Tong AW, Papayoti MH, Netto G, et al. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res 2001;7:691-703.
31. Harnett MM. CD40: a growing cytoplasmic tale. Sci STKE 2004:pe25.
32. Ishida T Kobayashi N, Tojo T, Ishida S, Yamamoto T, Inoue J. CD40 signaling-mediated induction of Bcl-XL, Cdk4, and Cdk6. Implication of their cooperation in selective B cell growth. J Immunol 1995;155: 5527-35.
33. Han H, Nomura T, Honjo T, Tsubata T. Differential modulation of cyclin-dependent kinase inhibitor p27Kip1 by negative signaling via the antigen receptor of B cells and positive signaling via CD40. Eur J Immunol 1996;26:2425-32.
34. Zhu N, Ramirez LM, Lee RL, Magnuson NS, Bishop GA, Gold MR. CD40 signaling in B cells regulates the expression of the Pim-1 kinase via the NF-κB pathway. J Immunol 2002;168:744-54.
35. Schauer SL, Wang Z, Sonenshein GE, Rothstein TL. Maintenance of nuclear factor-κB/Rel and c-myc expression during CD40 ligand rescue of WEHI 231 early B cells from receptor-mediated apoptosis through modulation of IκB proteins. J Immunol 1996; 157:81-6.
36. Galibert L, Burdin N, de Saint-Vis B, et al. CD40 and B cell antigen receptor dual triggering of resting B lymphocytes turns on a partial germinal center phenotype. J Exp Med 1996;183:77-85.
37. Igarashi H, Sakaguchi N. Telomerase activity is induced in human peripheral B lymphocytes by the stimulation to antigen receptor. Blood 1997;89: 1299-307.
38. Funakoshi S, Longo DL, Beckwith M, et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994;83:2787-94.
39. Hess S, Engelmann H. A novel function of CD40: induction of cell death in transformed cells. J Exp Med 1996;183:159-67.
40. Eliopoulos AG, Dawson CW, Mosialos G, et al. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 1996;13:2243-54.
41. von Leoprechting A, van der Bruggen P, Pahl HL, Aruffo A, Simon JC. Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res 1999;59:1287-94.
42. Hirano A, Longo DL, Taub DD, et al. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 1999;93: 2999-3007.
43. Ghamande S, Hylander BL, Oflazoglu E, Lele S, Fanslow W, Repasky EA. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res 2001;61:7556-62.
44. van den Oord JJ, Maes A, Stas M, et al. CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am J Pathol 1996;149:1953-61.
45. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003;63:4490-6.
46. Vonderheide RH, Dutcher JP, Anderson JE, et al. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 2001;19:3280-7.
47. Gladue R, Cole S, Donovan C, et al. In vivo efficacy of the CD40 agonist antibody CP-870,893 against a broad range of tumor types: impact of tumor CD40 expression, dendritic cells, and chemotherapy. J Clin Oncol 2006;24:103s.
48. Bedian V, Donovan C, Garder J, et al. In vitro characterization and pre-clinical pharmacokinetics of CP-870,893, a human anti-CD40 agonist antibody. J Clin Oncol 2006;24:109s.
49. Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007, in press.
50. Law CL, Gordon KA, Collier J, et al. Preclinical anti-lymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 2005;65: 8331-8.
51. Tai YT, Catley LP, Mitsiades CS, et al. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res 2004;64:2846-52.
52. Kelley SK, Gelzleichter T, Xie D, et al. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol 2006;148:1116-23.
53. Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Harrop K, Drachman JG. A humanized antibody against CD40 (SGN-40) is well tolerated and active in non-Hodgkin's lymphoma (NHL): results of a phase 1 study. J Clin Oncol 2006;24:430s.
54. Hussein MA, Berenson JR, Niesvizky R, et al. A phase I humanized anti-CD40 monoclonal antibody (SGN-40) in patients with multiple myeloma [abstract 2572]. Blood 2005;106.
55. Tong X, Georgakis GV, Long L, O'Brien S, Younes A, Luqman M. In vitro activity of a novel fully human anti-CD40 antibody CHIR-12.12 in chronic lymphocytic leukemia: blockade of CD40 activation and induction of ADCC [abstract 2504]. Blood 2005;106.
56. Schultze JL, Cardoso AA, Freeman GJ, et al. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci U S A 1995;92:8200-4.
57. Wierda WG, Cantwell MJ, Woods SJ, Ressenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000;96:2917-24.
58. Rousseau RF, Biagi E, Dutour A, et al. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood 2006; 107:1332-41.
59. Schultze JL, Michalak S, Seamon MJ, et al. CD40 activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997;100:2757-65.
60. Coughlin CM, Vance BA, Grupp SA, Vonderheide RH. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 2004;103:2046-54.
61. Schultze J, Johnson P. A stimulating new target for cancer immunotherapy. Lancet 1999;354:1225-7.
62. Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 2003;10:1-13.
63. Kapadia D, Fong L. CTLA-4 blockade: autoimmunity as treatment. J Clin Oncol 2005;23:8926-8.
64. Farzaneh L, Kasahara N, Farzaneh F. The strange case of TGN1412. Cancer Immunol Immunother 2007; 56:129-34.
65. + T cell expansion with variable dependence on type I IFN. J Exp Med 2004;199:775-84.
66. Uno T, Takeda K, Kojima Y, et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 2006;12:693-8.
67. Pham LV, Tamayo AT, Yoshimura LC, et al. A CD40 signalosome anchored in lipid rafts leads to constitutive activation of NF-κB and autonomous cell growth in B cell lymphomas. Immunity 2002;16:37-50.
68. McWhirter SM, Pullen SS, Holton JM, Crute JJ, Kehry MR, Alber T. Crystallographic analysis of CD40 recognition and signaling by human TRAF2. Proc Natl Acad Sci U S A 1999;96:8408-13.
69. Bishop GA, Hostager BS. The CD40-154 interaction in B cell-T cell liaisons. Cytokine Growth Factor Rev 2003;14:297-309.
70. Deng L, Wang C, Spencer E, et al. Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000;103:351-61.
71. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001;412:346-51.
72. Hostager BS, Bishop GA. Cutting edge: contrasting roles of TNF receptor-associated factor 2 (TRAF2) and TRAF3 in CD40-activated B lymphocyte differentiation. J Immunol 1999;162:6307-11.
73. Hanissian SH, Geha RS. Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells. Immunity 1997;6:379-87.
74. Ren CL, Morio T, Fu SM, Geha RS. Signal transduction via CD40 involves activation of lyn kinase and phosphatidylinositol-3-kinase, and phosphorylation of phospholipase Cγ2. J Exp Med 1994;179:673-80.
75. Fruman DA, Snapper SB, Yballe CM, et al. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85α. Science 1999;283: 393-7.
76. Suzuki H, Terauchi Y, Fujiwara M, et al. Xid-like immunodeficiency in mice with disruption of the p85α subunit of phosphoinositide 3-kinase. Science 1999;283:390-2.
77. Byrd JC, Flinn IW, Khan KD, et al. Pharmacokinetics and pharmacodynamics from a first-in-human phase 1 dose escalation study with antagonist anti-CD40 antibody, HCD 122 (formerly CHIR-12.12), in patients with relapsed and refractory chronic lymphocytic leukemia [abstract 2837]. Blood 2006;108.
78. Bensinger W, Jagannath S, Becker PS, et al. A phase 1 dose escalation study of a fully human, antagonist anti-CD40 antibody, HCD 122 (formerly CHIR-12.12), in patients with relapsed and refractory multiple myeloma [abstract 3575]. Blood 2006;108.